Table2.

Major haemorrhage by age subgroups

	No. of events (%/year)	No. of events (%/year)	Hazard ratio (95% CI)	P-value
ARISTOTLE	Apixaban 5 mg twice daily	Warfarin
<65	56 (1.2)	72 (1.5)	0.78 (0.55–1.11)	0.63
65 to <75	120 (2.0)	166 (2.8)	0.71 (0.56–0.89)
≥75	151 (3.3)	224 (5.2)	0.64 (0.52–0.79)
RE-LY	Dabigatran 110 mg twice daily	Warfarin
<75	138 (1.89)	215 (3.04)	0.62 (0.50–0.77)	0.0003
≥75	204 (4.43)	206 (4.37)	1.01 (0.83–1.23)
	Dabigatran 150 mg	Warfarin
<75	153 (2.12)	215 (3.04)	0.70 (0.57–0.86)	0.0001
≥75	246 (5.10)	206 (4.37)	1.18 (0.98–1.42)
ROCKET AF	Rivaroxaban 20 mg once daily	Warfarin
<65	59 (2.21)	59 (2.16)	1.02 (0.71–1.46)	0.59
65 to <75	113 (3.03)	123 (3.24)	0.94 (0.73–1.21)
≥75	223 (4.86)	204 (4.40)	1.11 (0.92–1.34)
ENGAGE AF-TIMI	Edoxaban 60 mg once daily	Warfarin		0.57
<75	(2.02)	(2.62)
≥75	(4.01)	(4.83)

The trials were different in the baseline risk for bleeding complications.